CD86: A Novel Prognostic Marker in Acute Lymphoblastic Leukemia Patients

Asmaa Mohamed Abdel Razek Saleh;

Abstract


Acute lymphoblastic leukemia (ALL) is a malignant
disorder of lymphoid progenitor cells that proliferate and
replace the normal hematopoietic cells of the bone marrow.
These lymphoblasts replacing the normal bone marrow
elements result in a marked decrease in the production of
normal blood cells.
It is the most common malignancy diagnosed in
patients younger than 15 years, accounting for 76% of all
leukemias in this age group. It accounts for only 20% of
adult acute leukemias.
There are many prognostic factors in ALL such as
age, sex, race, leukemic burden, laboratory criteria (initial
TLC, hemoglobin level, platelet count and serum
immunoglobulins), immunophenotyping, chromosomal
abnormalities, duration to induction of remission, drug
resistance profiles, and minimal residual disease.
Assessment of these factors is mandatory for therapeutic
assignment.
The B7-family molecule CD86 is a type I
transmembrane glycoprotein expressed on the surface of
antigen presenting cells (APCs). Cell surf


Other data

Title CD86: A Novel Prognostic Marker in Acute Lymphoblastic Leukemia Patients
Authors Asmaa Mohamed Abdel Razek Saleh
Issue Date 2018

Attached Files

File SizeFormat
J6884.pdf299.79 kBAdobe PDFView/Open
Recommend this item

Similar Items from Core Recommender Database

Google ScholarTM

Check

views 2 in Shams Scholar


Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.